Phesgo Approval Allows for Faster Administration of Pertuzumab and Trastuzumab
The FDA has approved Phesgo™ (pertuzumab, trastuzumab, hyaluronidase-zzxf; Genentech), in combination with chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer.